^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fingolimod

    i
    Other names: FTY 720, TDI-132, FTY-720, FTY720
    Company:
    Generic mfg.
    Drug class:
    S1PR modulator
    Related drugs:
    4d
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=240, Not yet recruiting, TG Therapeutics, Inc. | N=48 --> 240
    Enrollment change • Trial initiation date
    |
    Briumvi (ublituximab-xiiy) • fingolimod
    6d
    Polypharmacologic phosphoinositide modulation by FTY720 triggers endomembrane trafficking collapse and metabolic starvation in cancer cells. (PubMed, Biochem Biophys Res Commun)
    Building on our work with the structurally related compound KRP203, we show that high-dose FTY720 produces isozyme-divergent modulation across phosphoinositide kinases and biases PIKFYVE activity toward phosphatidylinositol, a pattern we term ASURA (Asymmetric Simultaneous Uncoupling of Related Activities). Patient-derived glioblastoma (GBM) neurospheres were sensitive to FTY720, and co-treatment with a PI3Kα-selective inhibitor augmented growth suppression in U87MG cells. Together, these data support a model in which ASURA-dose FTY720 disrupts phosphoinositide-regulated trafficking and nutrient access, imposing intracellular nutrient stress that culminates in tumor-cell death.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
    |
    fingolimod • mocravimod (KRP-203)
    6d
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=48, Not yet recruiting, TG Therapeutics, Inc.
    New P2/3 trial
    |
    Briumvi (ublituximab-xiiy) • fingolimod
    19d
    VOYAGE: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) (clinicaltrials.gov)
    P3, N=185, Not yet recruiting, Biogen
    New P3 trial
    |
    fingolimod
    1m
    Bevacizumab and Fingolimod Combination Therapy Induce Cytotoxicity and Apoptosis in Ovcar-3 Cells. (PubMed, Anticancer Agents Med Chem)
    The combination of Bevacizumab and Fingolimod presents a promising treatment strategy for ovarian cancer.
    Journal
    |
    CASP3 (Caspase 3) • CASP7 (Caspase 7) • ANXA5 (Annexin A5)
    |
    Avastin (bevacizumab) • fingolimod
    2ms
    NEOS: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov)
    P3, N=129, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2031 --> Mar 2031
    Trial completion date • Head-to-Head
    |
    fingolimod
    2ms
    NEOS: Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov)
    P3, N=129, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Mar 2027 --> Apr 2026
    Trial primary completion date • Head-to-Head
    |
    fingolimod
    2ms
    TG1101-RMS-PED304: Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) (2025-522257-19-00)
    P2/3, N=40, Not yet recruiting, Tg Therapeutics Inc.
    New P2/3 trial
    |
    Briumvi (ublituximab-xiiy) • fingolimod
    2ms
    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov)
    P2/3, N=240, Not yet recruiting, TG Therapeutics, Inc. | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Briumvi (ublituximab-xiiy) • fingolimod
    2ms
    SPHK1 deficiency promotes intestinal homeostasis by ameliorating ER stress-induced gastrointestinal injury during murine graft-versus-host disease. (PubMed, Sci China Life Sci)
    FTY720, an S1P receptor antagonist, significantly inhibits ER stress-induced IEC injury. Our findings highlight the pathogenic role of host SPHK1 in gastrointestinal injury during aGVHD and suggest that targeting SPHK1 could be a therapeutic strategy for managing this condition.
    Preclinical • Journal
    |
    SPHK1 (Sphingosine Kinase 1)
    |
    fingolimod
    2ms
    In-silico characterization of deleterious non-synonymous SNPs in the human S1PR1 gene reveals structural instability and altered ligand affinity. (PubMed, PLoS One)
    Molecular docking and dynamics simulations showed that R120P and F125S weaken binding affinity for natural agonist sphingosine-1-phosphate (S1P) and FTY720P, while antagonist W146 retained strong binding...Collectively, these findings identified high-risk nsSNPs in S1PR1 gene with potential structural and functional implications, particularly in diseases involving impaired receptor signaling. These findings enhanced our understanding of how specific nsSNPs can influence disease susceptibility, drug response, and receptor function, paving the way for precision medicine approaches in treating autoimmune and inflammatory disorders.
    Journal
    |
    S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    |
    fingolimod